Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
UK delivery is 4.50 by Royal Mail Tracked 24, or free once your basket reaches 45 (29.01 away at this price)
BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC)
Mild nausea has also been reported in subjects who are administered doses in excess of 1mg
mobile IV hydration therapy market reached approximately $568.5 million in 2024 and is projected to expand at a 10.4% CAGR through 2030
US$ 24.44
US$ 23.23
US$ 22.78
US$ 28.92
US$ 27.75
US$ 28.36
US$ 20.26
US$ 27.11
US$ 22.99
US$ 24.98
US$ 28.01
US$ 20.52
US$ 29.68
